Main category: breast cancer
Also included is: cosmetic medicine/plastic surgery
Article date: January 26, 2010-5: 00 PST window. fbAsyncInit = function () {FB. init ({appId: ' aa16a4bf93f23f07eb33109d5f1134d3 ', true, State: cookie: true, real, xfbml: channelUrl: ' http://www.medicalnewstoday.com/scripts/facebooklike.html '});}; (function() {var e = document.createElement("p") (' script '); e. async = true; and .src = document.location.protocol + '//' connect.facebook.net/en_US/all.js; document.getElementById (' fb-root ') appendChild (e);}());
email to a friend 
printer friendly 
views
Clinical experience has published in over 2000 patients who received autologous grafts fats has shown no evidence of increased risk of developing metastasis or recurrence of breast cancer in contrast with laboratory data. The newly published review entitled "Cancer risks of autologous fat grafting for breast" in the January issue of the journal of cosmetic surgery of the American Society of aesthetic plastic surgery discusses the differences between clinical data and certain laboratory-based scientific literature on fat grafting for breast procedures. This includes those procedures whereby the grafting was enriched with stem cells derived from adipose tissue and regenerative cells (ADRCs).
The article, written by John Fraser, Ph. d. and Marc Hedrick, MD of Cytori Therapeutics Therapeutics (NASADQ: CYTX) and Steve Cohen, MD, one of the leading plastic surgeons in the United States, shall assess critically the theoretical concerns raised by fat grafting for breast procedures (in particular for women who have undergone treatment for breast cancer).
Through a comprehensive review of published reports, the article explores the potential problems and concludes that the apparent discrepancy between the data laboratory and the clinic are the result of applying artificial conditions used in some laboratory studies which do not arise in a clinical setting. This analysis is consistent with pre-clinical studies, demonstrating Cytori Therapeutics enriched cell grafting fat did not increase the risk of developing breast cancer or metastases that in some situations, actually reduced the growth of cancer.
"Patient safety is of prime importance in the development of products PureGraft ? and ? Celution," said Christopher Calhoun, CEO Cytori Therapeutics Therapeutics. "There is a greater demand patient and physician for our technologies and this careful review supports our view that our recommended fat grafting techniques are safe in the breast. We will continue to conduct our security research and analyze data from outside sources for Cytori Therapeutics, as part of legislative progress and the final adoption of our products. "
The January issue of the journal surgery is now available online here.
Source:
Cytori Therapeutics
Note: any medical information published on this website are not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
All opinions are moderated before being added.
Please note that we publish your name, but we not publish your email address. It is used only to let you know when your message has been posted. We do not use it for other purposes. Please see our privacy policy for more information.
If you write about specific medicines or operations, please do not of health professionals to name by name.
Contact our news editors
For corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical or health News News Releases:
No comments:
Post a Comment